Title |
The TICOPA protocol (TIght COntrol of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis
|
---|---|
Published in |
BMC Musculoskeletal Disorders, March 2013
|
DOI | 10.1186/1471-2474-14-101 |
Pubmed ID | |
Authors |
Laura C Coates, Nuria Navarro-Coy, Sarah R Brown, Sarah Brown, Lucy McParland, Howard Collier, Emma Skinner, Jennifer Law, Anna Moverley, Sue Pavitt, Claire Hulme, Paul Emery, Philip G Conaghan, Philip S Helliwell |
Abstract |
Psoriatic arthritis (PsA) is estimated to occur in 10-15% of people with psoriasis and accounts for 13% of people attending early arthritis clinics. With an increasing awareness of the poor outcomes associated with PsA and the availability of new effective, but costly, treatments, there is an urgent need to research the optimal treatment for patients with PsA. The aim of the TICOPA study is to establish whether, in treatment naive early PsA patients, "tight control" intensive management with protocol driven therapies and pre-defined objective targets for treatment can improve clinical outcome compared to standard care alone. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 33% |
United Kingdom | 1 | 33% |
Unknown | 1 | 33% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 67% |
Practitioners (doctors, other healthcare professionals) | 1 | 33% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 1 | <1% |
Unknown | 121 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 19 | 16% |
Student > Master | 15 | 12% |
Other | 14 | 11% |
Professor | 11 | 9% |
Student > Postgraduate | 9 | 7% |
Other | 30 | 25% |
Unknown | 24 | 20% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 66 | 54% |
Nursing and Health Professions | 6 | 5% |
Agricultural and Biological Sciences | 6 | 5% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 3% |
Economics, Econometrics and Finance | 3 | 2% |
Other | 8 | 7% |
Unknown | 29 | 24% |